Enhancing HIV-1 Specific Immunity as a Therapeutic Strategy in Aids

  • Robert T. Schooley
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 394)


Over the past several years it has become apparent that HIV-1 infection is characterized by a prolonged struggle between a lymphotropic retrovirus and a vigorous humoral and cellular immune response. Following initial infection, HIV-1 replicates to high titers in the peripheral blood, and other lymphoid tissues. 1,2 During this explosive phase of viral replication, HIV-1 RNA copy numbers in plasma approach or exceed those seen in late stage disease.3 Over an 8–12 week period, viral titres in plasma drop precipitously as a vigorous cellular and humoral immune response develops.4 The precipitous decline in viral load which results from the immune response to HIV is several orders of magnitude greater than the reduction which occurs following therapy with nucleoside analog reverse transcriptase inhibitors,5 and lasts an average of 6–9 years. The profound and prolonged decline in viral load which is attributable to the virus-specific immune response during primary infection has suggested that augmenting this immune response in infected individuals may prolong both the asymptomatic period of HIV infection and survival.


Human Immunodeficiency Virus Human Immunodeficiency Virus Type Specific Immune Response Passive Immunotherapy Recombinant Human Monoclonal Antibody 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Daar ES Mough T Meyer RD and Ho DD: Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N Engl J Med. 1991; 324: 961–4.CrossRefGoogle Scholar
  2. 2.
    Clark SJ Saag MS Decker WD et. al.: High titers of cytopathic virus in plasma of patients withsymptomatic primary HIV 1 infection. N Engl J Med 1991; 324: 954–60.PubMedCrossRefGoogle Scholar
  3. 3.
    Ho DD Moudgil T Alam M Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. New Engl J Med 321, 1621–1625.Google Scholar
  4. 4.
    Koup RA Safrit JT Cao Y et. al.: Temporal association of cellular immune responses with theinitial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994; 68: 4650–5PubMedGoogle Scholar
  5. 5.
    Holodniy M Katzenstein D Winters M, et. al., Measurement of HIV virus load and genotypicresistance by gene amplification in asymptomatic subjects treated with combination therapy.JAIDS 1993; 6: 36.Google Scholar
  6. 6.
    McKnight A Clapham PR Goudsmit J et. al. Development of HIV-1 group-specific neutralizing antibodies after seroconversion. AIDS 1992; 8: 799–802.Google Scholar
  7. 7.
    Borrow P Lewicki H Hahn BH Shaw GM and Oldstone MB: Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994; 68: 6103–10.Google Scholar
  8. 8.
    Walker BD Chakrabarti S Moss B Paradis TJ Flynn T Durno AG Blumberg RS Kaplan JC Hirsch MS and Schooley RT. HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature. 1987; 328: 345–348.CrossRefGoogle Scholar
  9. 9.
    Ho DD Rota TR Hirsch MS. Antibody to lymphadenopathy associated virus in AIDS. N Engl J Med. 1985: 312; 649–50.CrossRefGoogle Scholar
  10. 10.
    Cao Y Qin L Zhang L Safrit J Ho DD. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med 1995; 332: 201–8.CrossRefGoogle Scholar
  11. 11.
    Saag MS Hahn BH Gibbons J Extensive variation of human immunodeficiency virus in vivo. Nature 1988; 334: 440–4.CrossRefGoogle Scholar
  12. 12.
    Jackson GG Rubenis M Knigge, Passive immunoneutralization of HIV in patients with advanced AIDS. Lancet 1988; ii: 647–51.Google Scholar
  13. 13.
    Vittecoq D Mattlinger B Bare-Sinoussi F et. al. Passive immunotherapy in AIDS: A randomized trial of serial human immunodeficiency virus-positive transfusions of plasma rich in p24 antibodies versus transfusion of seronegative plasma. J Infect Dis; 1992: 165: 364–8.CrossRefGoogle Scholar
  14. 14.
    Lefrere JJ Vittecoq D and the French Passive Immunotherapy Group. Passive immunotherapy in AIDS: Results of a double blind randomized phase II study. Abstract L12. First National Conference on Human Retroviruses and Related Infections. American Society for Microbiology. Washington DC. December 12–16, 1993.Google Scholar
  15. 15.
    Daar ES Li XL Moudgil T and Ho DD. High concentrations of recombinant soluble CD4 are required to neutralize primary isolates of human immunodeficiency virus type 1 isolates. Proc Nat Acad Sci USA. 1990; 87: 6574–8.CrossRefGoogle Scholar
  16. 16.
    Purtscher M, Trkola A, Gruber G, Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. AIDS Research and Human Retroviruses 1994; 10: 1651–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Burton DR, Pyati J, Koduri R, et. al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994; 266: 1024–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Zolla-Pazner S Laal S Burda S Buchbinder. A human monoclonal antibodies to HIV-1 define synergistic activities leading to enhanced neutralization. Antibiot Chemother 1994; 46: 38–47Google Scholar
  19. 19.
    Deresinski SC, Israelski DI, Frascino RJ, et. al. Randomized multicenter comparison of treatment of HIV infected patients: activated CD8+ cells plus rIL-2 plus antiretroviral (AR) therapy vs. rIL-2 plus AR therapy vs AR therapy alone. Abstract 206. Second National Conference on Human Retroviruses and Related Infections. American Society for Microbiology. Washington DC. January 29 - February 2, 1995.Google Scholar
  20. 20.
    Lieberman J Fabry JA Skolnik PR Parkerson GR Fong DM Kagan J Standiford H Lee E Landry B Immunotherapy with autologous HIV-specific CTL. Int Conf AIDS ( 1994 Aug 7–12 ) 10: 220 (abstract no. PB0311).Google Scholar
  21. 21.
    Roberts MR Qin L Zhang D et. al. Targeting of human immunodeficiency virus-infected cells by CD8+ T lymphocytes armed with universal T-cell receptors. Blood 1994; 84: 2878–89.Google Scholar
  22. 22.
    Redfield RR Birx DL Ketter N Tramont E Polonis V Davis C, A phase 1 evaluation of the immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. N Engl J Med 1991; 324: 1677–84.CrossRefGoogle Scholar
  23. 23.
    Kundu SK Katzenstein D Moses LE and Merigan TC. (1992) Enhancement of human immunodeficiency virus (HIV)-specific CD4+ and CD8+ cytotoxic T-lymphocyte activities in HIV-infected asymptomatic patients given recombinant gp160 vaccine. Proc Natl Acad Sci USA. 89, 11204–8.CrossRefGoogle Scholar
  24. 24.
    Trauger RJ, Ferre F, Daigle FC, et. al. Effect of inununization with inactivated envelope depleted human immunodeficiency virus type 1 (HIV-1) inununogen in incomplete Freund’s adjuvant on HIV-1 immunity, viral DNA, and percentage of CD4 cells. J Infect Dis 1994; 169: 1256–64.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • Robert T. Schooley

There are no affiliations available

Personalised recommendations